石四药集团(02005):取得盐酸多沙普仑注射液(5ml:100mg)的药品生产注册批件

智通财经
Mar 03

智通财经APP讯,石四药集团(02005)发布公告,集团已取得中国国家药品监督管理局有关盐酸多沙普仑注射液(5ml:100mg)的药品生产注册批件,属于化学药品第3类,视同通过一致性评价。集团的盐酸多沙普仑注射液是国内企业首家获批,主要用于治疗呼吸衰竭。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10